Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Noncontrolling Interest
Beginning Balance at Dec. 31, 2020	$ 743,266	$ 14	$ 1,253,971	$ 893	$ (511,612)
Beginning Balance, Shares at Dec. 31, 2020		137,646,896
Issuance of common stock upon exercise of common stock warrant, Shares		54,162
Issuance of common stock for cash upon exercise of stock options	26,484		26,484
Issuance of common stock for cash upon exercise of stock options, Shares		3,674,057
Vesting of restricted stock units		18,750
Share-based compensation	43,251		43,251
Capital contributions for Digital Biotechnologies, Inc.	429		300			$ 129
Other comprehensive (loss) income	(2,030)			(2,030)
Net loss	(207,298)				(207,279)	(19)
Ending Balance at Dec. 31, 2021	604,102	$ 14	1,324,006	(1,137)	(718,891)	110
Ending Balance, Shares at Dec. 31, 2021		141,393,865
Issuance of common stock for cash upon exercise of stock options	7,866		7,866
Issuance of common stock for cash upon exercise of stock options, Shares		1,406,500
Vesting of restricted stock units		304,637
Share-based compensation	55,477		55,477
Other comprehensive (loss) income	(2,979)			(2,979)
Net loss	(200,368)				(200,191)	(177)
Ending Balance at Dec. 31, 2022	464,098	$ 14	1,387,349	(4,116)	(919,082)	(67)
Ending Balance, Shares at Dec. 31, 2022		143,105,002
Issuance of common stock for cash upon exercise of stock options	$ 2,245		2,245
Issuance of common stock for cash upon exercise of stock options, Shares	470,405	470,405
Vesting of restricted stock units		1,506,864
Share-based compensation	$ 62,908		62,908
Other comprehensive (loss) income	4,331			4,331
Net loss	(225,304)				(225,250)	(54)
Ending Balance at Dec. 31, 2023	$ 308,278	$ 14	$ 1,452,502	$ 215	$ (1,144,332)	$ (121)
Ending Balance, Shares at Dec. 31, 2023		145,082,271